Skip to main content
. 2022 Jul 26;10(8):1186. doi: 10.3390/vaccines10081186

Figure 4.

Figure 4

Significantly reduced levels of anti-SARS-CoV-2 inhibiting antibodies 6 months after two BNT162b2 vaccine doses in all recruited subjects. (A) Ability of serum from healthy controls (HCs, shown in purple), patients with IBD receiving non-anti-TNFα treatment (non-anti-TNFα, shown in blue) and patients with IBD receiving anti-TNFα treatment (anti-TNFα, shown in red) to inhibit SARS-CoV-2 RBD binding to ACE2 receptor. Values measured with ELISA and presented as % inhibition (y axis). Visit 3 (filled circles), visit 4 (open triangles)—after two vaccine doses, 1 and 6 months, respectively. Zero inhibition was set as the value of RBD without added sera. Statistical analysis was carried out using independent sample Kruskal–Wallis test, ****—p < 0.0001. (B) Correlation between anti-S titer and inhibition responses. (C) Correlation between neutralizing activity and inhibition responses. Abbreviations: RBD—receptor-binding domain; ACE2—angiotensin-converting enzyme-2.